Effect of tislelizumab combined with platinum-containing chemotherapy on treatment of patients with advanced non-small cell lung cancer
Tong Jun
Fu Changzheng
Wu Fusheng
Abstract：Objective To explore the therapeutic effect of tislelizumab combined with platinum-containing chemotherapy on patients with advanced non-small cell lung cancer(NSCLC).Methods A total of 90 patients with advanced NSCLC ad-mitted to the Wuwei City People's Hospital from March 2022 to March 2024 were divided into the platinum-containing scheme group(45 cases)treated with platinum-containing regimen and the monoclonal antibody combined with platinum group(45 cases)treated with tislelizumab combined with platinum-containing chemotherapy.All patients were treated for 6 cycles.The efficacy,serum cytokines,tumor markers,peripheral blood cell levels and adverse reactions of the two groups were statistically analyzed.Results After the treatment,the total remission rates of the monoclonal antibody combined with platinum group and the plat-inum-containing scheme group were 73.33%(33/45)and 51.11%(23/45),respectively,with statistical significance(χ2=4.727,P=0.030).After the treatment,the levels of serum thymidine kinase 1(TK1),proliferating cell nuclear antigen(PCNA)and vascular endothelial growth factor(VEGF)in the monoclonal antibody combined with platinum group and the platinum-containing scheme group were decreased.The above indexes in the monoclonal antibody combined with platinum group were(2.02±0.41)ng·mL-1,(322.08±48.77)pg·mL-1 and(148.62±14.33)pg·mL-1,lower than(2.97±0.66)ng·mL-1,(405.72±59.60)pg·mL-1 and(183.52±19.40)pg·mL-1 in the platinum-containing scheme group(t=8.202,7.286,9.707,all P<0.05).After the treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and squamous cell carcinoma antigen(SCC)in the monoclo-nal antibody combined with platinum group and the platinum-containing scheme group were decreased.The levels of serum CEA,CA125 and SCC in the monoclonal antibody combined with platinum group were(41.07±5.41)ng·mL-1,(13.44±2.51)U·mL-1 and(19.78±2.16)mg·mL-1,lower than(50.82±6.72)ng·mL-1,(20.17±3.19)U·mL-1 and(31.52±4.18)mg·mL-1 in the platinum-contain-ing scheme group(t=7.581,11.122,16.738,all P<0.05).After the treatment,the levels of peripheral blood platelet/lymphocyte ratio(PLR)and neutrophil/lymphocyte ratio(NLR)in the monoclonal antibody combined with platinum group and the platinum-contain-ing scheme group decreased,and the level of peripheral blood lymphocyte/monocyte ratio(LMR)increased.The levels of peripher-al blood PLR and NLR in the monoclonal antibody combined with platinum group were(111.85±21.37)and(1.98±0.37),lower than(143.27±23.83)and(3.18±0.52)in the platinum-containing scheme group;the level of peripheral blood LMR in the monoclonal antibody combined with platinum group was(8.02±0.72),higher than(5.98±0.59)in the platinum-containing scheme group(t=6.585,12.613,14.701,all P<0.05).The total incidences of adverse reactions in the platinum-containing scheme group and the monoclonal antibody combined with platinum group were 20.00%(9/45)and 22.22%(10/45)respectively,and there was no statistically signifi-cant difference between the two groups(χ2=0.067,P=0.796).Conclusion Tislelizumab combined with platinum-containing che-motherapy in the treatment of advanced NSCLC patients can effectively regulate the serum cytokine and peripheral blood cell level,reduce the level of tumor markers,and relieve the condition of patients,while it does not increase the risk of adverse reactions,with the efficacy and safety favorable.
Keywords：Non-small cell lung cancerTislelizumabLate-stage cancerCisplatinAlbumin paclitaxel
Publication Date：2025-06-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 379-383 )